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Abstract
Background—Although symptoms of sleepiness and fatigue are common among adults with
Chronic Kidney Disease (CKD), little is known about the prevalence of these symptoms in children
with CKD.
Study Design—Cross-sectional analysis within a cohort study.
Setting & Participants—We describe the frequency and severity of sleep problems and fatigue,
and we assess the extent of their association with measured glomerular filtration rate (mGFR) and
Health-Related Quality of Life (HRQOL) among 301 participants of the Chronic Kidney Disease in
Children cohort.
Outcomes and Measurements—Sleep and fatigue-related items from the Pediatric Quality of
Life Inventory 4.0 Generic Scales and the CKD-related Symptoms List were used.
Results—Median mGFR was 42.0 ml/min/1.73m2 (25th–75th percentiles, 31.2–53.2) [EF1]and
median age was 13.9 years (25th–75th percentiles, 10.8–16.2). Children with mGFR 40-<50, 30-
<40, or <30 had 2.07 (95% CI, 1.05–4.09), 2.35 (95% CI 1.17, 4.72) and 2.59 (95% CI 1.15, 5.85)
higher odds of having more severe parent reports of low energy than children with mGFR ≥50.
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Compared to participants with mGFR ≥50, those with mGFR <30 had 3.92 (95% CI 1.37, 11.17)
higher odds of reporting more severe weakness, and those with mGFR 40-<50 had 2.95 (95% CI
1.26, 6.88) higher odds of falling asleep during the day. Low energy, trouble sleeping and weakness
were associated with lower HRQOL scores.
Limitations—Symptoms of sleep and fatigue represent the child or parent’s perception of symptom
severity, while individual items can lead to imprecise measurements of sleep and fatigue.
Conclusions—Lower mGFR was associated with increased weakness, low energy, and daytime
sleepiness. Furthermore, a strong association between trouble sleeping, low energy and weakness
with decrements in overall HRQOL was observed. Detection and treatment of poor sleep and fatigue
may improve the development and HRQOL of children and adolescents with CKD.
Index words
children; adolescents; chronic kidney disease; sleep; fatigue; glomerular filtration rate; health-related
quality of life
Introduction
Chronic Kidney Disease (CKD) and its consequences are a public health concern, as many
children currently being treated for CKD are progressing to End Stage Renal Disease (ESRD).
In parallel, more attention is being paid to the educational, psychosocial, emotional and
physical health of children and adolescents with CKD (1). Health and growth in children is
promoted by adequate sleep, and previous work indicates that sleep problems are prevalent
among children with chronic illnesses (2). One of the most compelling reasons why a better
understanding of symptoms of sleepiness and fatigue should feature prominently in the care
of children with CKD, is that sleep disturbances can have a deleterious effect on a child’s
behavior, ability to learn and physical development (3).
While sleep and fatigue symptoms have been widely documented among adults with CKD and
ESRD (4), assessment of sleep and fatigue problems in children with CKD has been limited.
One study demonstrated that 86% of children and young adults with ESRD on dialysis had a
sleep problem (5), while another study of children with CKD stages 1–4 found an increased
prevalence of restless legs syndrome (35%) compared to children without CKD (6). The paucity
of data on the prevalence and correlates of sleep and fatigue symptoms in children with mild
to moderate CKD provides the impetus for this report, which uses data collected from the
Chronic Kidney Disease in Children (CKiD) study, a large North American cohort of children
and adolescents with mild to moderate CKD (7). Since many conditions that increase the risk
of sleep disturbances and fatigue in children on dialysis (e.g., uremia, anemia, inadequate iron
stores, malnutrition, edema and acidosis) are also present among children with mild to moderate
CKD (1,8–13), we hypothesized that CKD severity, as quantified by measured glomerular
filtration rate (mGFR), would be associated with symptoms of sleep problems (having trouble
sleeping, waking up too early, falling asleep during the day and decreased alertness) and aspects
of fatigue (low energy and weakness). Furthermore, we examined the extent to which sleep
and fatigue symptoms were associated with poorer health-related quality of life (HRQOL)
hypothesizing that sleep and daytime functioning are associated.
Methods
Study Population
Eligible participants for the CKiD study were 1–16 years of age with mild to moderate CKD,
(GFR between 30 and 90 ml/min/1.73m2 by the Schwartz formula) (14). This report presents
cross-sectional data from patients older that 8 years old at the first annual follow-up visit which
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was the first time HRQOL and CKD-related symptoms data were collected concurrently. The
age cutoff was chosen in order to facilitate self-report testing with the HRQOL measurement.
Demographics, height, weight, vital signs, iohexol-based measurements of GFR (15,16),
medical history and medication use were simultaneously obtained. The CKiD study was
approved by the Human Subjects Review Boards at all participating sites in the United States
and Canada.
Primary Outcomes
Aspects of HRQOL were assessed with the Pediatric Quality of Life Inventory Version 4.0
Generic Scales (PedsQL), an instrument specifically developed to evaluate the physical,
school, emotional and social domains of HRQOL in children that has been previously validated
in healthy and patient populations (17,18). The individual items of “having trouble sleeping”
from the PedsQL emotional domain and “low energy level” from the PedsQL physical domain
were extracted from both the child and parent surveys in order to evaluate the prevalence of
sleep problems and fatigue, respectively. The frequency of having trouble sleeping and low
energy within the past month was classified into one of four categories: “never”; “almost
never”; “sometimes”; “often/almost always”. Overall PedsQL scores range from 0 to 100 with
higher scores denoting better quality of life. The PedsQL was also scored without the “low
energy” and “trouble sleeping items” from both the parent and child surveys. No substantial
changes were observed in the internal consistency and reliability (Cronbach alpha) with the
removal of these two items from the PedsQL Physical and Emotional domains.
The prevalence of sleep problems and fatigue was also determined by the CKiD Symptoms
List (Item S1, provided as online supplementary material available with this article at
www.ajkd.org) which was adapted from the Chronic Renal Insufficiency Cohort (CRIC) Study
(19). Participants and/or parents were instructed to indicate the number of days in the last month
in which they/or their child had experienced any of the following symptoms: “weakness”,
“waking up early”, “falling asleep during the day,” or “decreased alertness.” If the response
exceeded 0 days, the participant and/or parent rated the level of severity as: “mild”; “moderate
- severe.” Reports of 0 days were classified as “no symptoms”.
Sleep symptoms were quantified by reports of having trouble sleeping, waking up early, falling
asleep during the day, and decreased alertness. Presence of fatigue was assessed by reports of
low energy level and weakness.
Primary Exposure and Covariates
The primary exposure was mGFR determined by plasma disappearance of iohexol in a two-
compartment system measured at 10, 30, 120, and 300 min after infusion. Iohexol is a safe,
nonionic, low-osmolar contrast agent of molecular weight 821 Da used[ND2] as a filtration
marker of the kidneys. It is not secreted, metabolized, or reabsorbed by the kidney (20–22),
and has <2% plasma protein binding (20,23) and nearly negligible extrarenal clearance (24–
26). In all analyses, four mGFR categories were utilized: ≥50, 40-<50, 30-<40 and <30 ml/
min/1.73m2. Blood samples were collected at the time of the study visit and analyzed at the
Central Biochemistry Laboratory (University of Rochester, Rochester, NY). A complete blood
count was also obtained locally.
Covariates included (1) demographic factors: age (8-≤11, 11-≤14, 14-≤16, and >16 years), sex,
race (White, African-American), income of primary household members (≤$36,000, $36,001
to $75,000, and >$75,000); (2) CKD-related factors: percent of life with CKD (<25%, 25%-
<75%, 75% –-100%), primary cause of CKD (glomerulonephritis, non-glomerulonephritis),;
(3) growth markers: low birth weight (<2500g, ≥2500g), age and sex specific body mass index
(BMI) percentiles (<35th, 35th-<60th, 60th-<85th and >85th percentile), Tanner Stage (i.e.,
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characterization of the physical development of the children and adolescents in this study and
was defined by physical measurements of development, based on external primary and
secondary sex characteristics, such as the size of the breasts, genitalia, and development of
pubic hair) (I–III, IV–V).; (4) Co-morbidities: hypertension (hypertensive [≥95th percentile of
age-sex-height specific systolic or diastolic blood pressure, or as self-reported hypertension
plus current treatment with antihypertensive medications], not hypertensive) (27,28), anemia
(hemoglobin level <11 g/dL, v.s. >11 g/dL) (29); and (5) current medication use:
antihypertensives, central nervous system (CNS) stimulating agents and antidepressants.
Statistical Analyses
Non-parametric statistics (e.g., medians, 25th–75th percentiles) as well as percentages were
used to describe the characteristics of the study population. Unadjusted and adjusted ordinal
logistic regression models were used to quantify the degree of association mGFR and each of
the covariates had with the sleep and fatigue outcomes. Covariates were included in adjusted
models for a particular outcome if they were significant at the 0.1 significance level in
unadjusted analysis for that outcome.
In order to assess the association of sleep problems and fatigue on overall HRQOL, linear
regression was used with the child and parent overall PedsQL scores as the response variables
and the individual sleep and fatigue item responses as the exposures. Each linear regression
model contained an intercept corresponding to the mean response of the reference group and
regression coefficients corresponding to the mean differences in responses between each group
and the reference group. All analyses were adjusted for age, sex, mGFR stage, income,
percentage of life with CKD, BMI percentile, low birth weight, hypertension, and anemia, and
were performed using SAS 9.1 statistical software (SAS Institute, www.sas.com).
Results
Characteristics of Study Population
As of February 2009, 568 participants completed their baseline study visit and 444 (78%)
completed their first annual follow-up visit. Of the 444, 341 (77%) were at least 8 years of age
at their first annual follow-up visit; among whom 323 (95%) had data available for at least one
HRQOL or CKD-related outcome of interest. The final study population for the present study
consisted of 301 (93%) CKiD participants who also had a valid mGFR at their first follow-up
visit.
The 301 participants had a median age of 13.9 years (IQR 10.8 – 16.2), 61% were male, 72%
were White, and 60% were Tanner stage I–III (Table 1). Thirty-six percent of the participants
lived in a low-income household and 17% had low birth weight. The median mGFR was 42.0
ml/min/1.73m2 (25t–75th percentiles, 31.2–53.2) and 23% had been diagnosed as having
glomerulonephritis (GN). The majority of study participants were using antihypertensives
(73%). A small percentage reported using antidepressants (4%) and CNS stimulating agents
(5%).
Prevalence of Behavioral Sleep Problems and Fatigue Symptoms
A total of 263 participants had data available on at least one of the four outcomes: child/parent
report of child’s trouble sleeping or child/parent report of child’s low energy. “Often” or
“almost always” was reported for at least one of these outcomes in the past month for 29%
(n=75) of the study participants. The prevalence of “often” or “almost always” was 12%, 9%,
11%, and 14% for child report of trouble sleeping, parent report of trouble sleeping, child report
of low energy and parent report of low energy, respectively (Figure 1). Both child and parent
reports of low energy were more frequent for decreased levels of mGFR. Furthermore, 281
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participants reported on at least one of the symptom-related outcomes (weakness, waking up
early, falling asleep during the day, and decreased alertness). “Moderate” or “severe” was
recorded for at least one of these outcomes for 25% (n=69) of the participants. The prevalence
of “moderate” or “severe” symptoms was 16%, 3%, 10% and 4% for weakness, waking up
early, falling asleep during the day and decreased alertness, respectively (Figure 2). The
severity of weakness and falling asleep during the day increased for decreased levels of mGFR.
Univariate and Multivariate Analyses of PedsQL Sleep and Fatigue Outcomes
In the univariate analysis of PedsQL sleep and fatigue outcomes (Table S1, provided as online
supplementary material available with this article at www.ajkd.org) parents’ report of low
energy was inversely associated with mGFR levels. Neither the frequency of childrens’ reports
of low energy nor trouble sleeping was significantly associated with mGFR level. Parents of
patients with an annual family income of >$75,000 reported a significantly lower frequency
of low energy compared to parents of patients with an annual family income of <$36,000.
Having CKD for ≥ 25% of life was associated with a significantly lower frequency of low
energy compared to having CKD for < 25% of life. Anemia was associated with a significantly
greater frequency of low energy, while hypertensive patients reported a significantly lower
frequency of trouble sleeping. Age, sex, race, type of CKD diagnosis, birth weight, BMI, and
Tanner stage were not associated with any of the PedsQL outcomes.
In the multivariate analysis, parents of patients with lower mGFR levels had higher odds, of
reporting a greater frequency of low energy than parents of patients with mGFR ≥50 ml/min/
1.73m2 (Table 2). However, patients’ reports of low energy and both patients’ and parents of
patients’ reports of trouble sleeping were not significantly associated with mGFR levels.
Parents of patients with an annual family income of >$75,000 reported significantly lower
frequencies of both trouble sleeping and low energy compared to parents of patients with an
annual family income of <$36,000. Furthermore, patients with CKD for ≥ 25 % of their life
reported significantly less low energy compared to patients with CKD for <25% of life.
Univariate and Multivariate Analyses of Chronic Kidney Disease-Related Symptoms of Sleep
and Fatigue
In the univariate analyses of the associations of symptoms of sleep and fatigue (Table S2,
provided as online supplementary material available with this article at www.ajkd.org) reports
of increased weakness and greater severity of falling asleep during the day were more common
in those with mGFR <30 ml/min/1.73m2 than among those with mGFR ≥50 ml/min/1.73m2.
Waking up early and decreased alertness was not associated with mGFR. Participants 14 years
of age and older were more likely to report a greater severity of falling asleep during the day
than participants 11 years of age and younger. Higher annual family income (>$36,000), a
greater percentage of life with CKD (≥25%) and a BMI >85th percentile were significantly
associated with less severe weakness, while the presence of anemia was significantly associated
with increased weakness.
In the multivariate analysis, patients with mGFR <30 ml/min/1.73m2 were almost four times
more likely to report more severe weakness than patients with mGFR ≥50 ml/min/1.73m2
(Table 3). Patients with mGFR between 40-<50 were three times more likely to report more
severe problems of falling asleep during the day than patients with mGFR ≥50 ml/min/
1.73m2. Patients 14 years of age and older were significantly more likely to report more severe
problems of falling asleep during the day than patients 11 years of age and younger. Patients
from homes with higher annual family incomes were less likely to report severe weakness and
falling asleep during the day than patients from low annual income families (≤$36,000).
Patients with CKD for ≥25% of their lifetime were less likely to report severe weakness than
patients with CKD for <25% of their life. Finally, anemic patients and patients who were born
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<2500g were more likely to report more severe weakness than patients born with a normal
weight or non-anemic patients.
Association of Medications with Sleep and Fatigue Items
While the prevalence of antihypertensive medication use was high (73%), its use was not
related to mGFR level or to any of the sleep and fatigue outcomes. Study participants who
reported using antidepressants (4%) or CNS stimulating agents (5%) reported a greater
frequency of trouble sleeping than those who did not report using antidepressants (ORs of
12.74 [95% CI 3.56, 45.62] and 7.86 (95% CI 2.19, 28.22) for child report and parent report,
respectively) or CNS stimulating agents (ORs of 4.21[95% CI 1.36,13.02) and 2.76 [95% CI
0.90, 8.43] for child report and parent report, respectively) after adjustment (not shown). None
of the significant findings presented in Table 2 and Table 3 were attenuated when participants
using antidepressants or CNS stimulating agents were excluded from analyses.
Association of Sleep and Fatigue items with standardized HRQOL outcomes
Figure 3 depicts the PedsQL mean scores and 95% confidence intervals for both the parent and
child for each of the trouble sleeping and low energy outcome adjusted for age, sex, mGFR
stage, income, percentage of life with CKD, BMI percentile, low birth weight, hypertension,
and anemia. A report of “often” or “almost always” having trouble sleeping or low energy by
either the parent or the child was associated with lower PedsQL scores.
The relationship between children’s overall PedsQL mean scores and symptoms of sleep and
fatigue after adjusting for age, sex, mGFR stage, income, percentage of life with CKD, BMI
percentile, low birth weight, hypertension, and anemia are shown in Figure 4. A report of
“moderate” or “severe” weakness was associated with lower quality of life. None of the other
symptoms were associated with the childrens’ overall PedsQL scores. The aforementioned
relations did not substantially change when the PedsQL overall scores were calculated without
excluding the “trouble sleeping” and “low energy” items.
Discussion
This report extends our understanding of symptoms of sleep and fatigue and their correlates in
children and adolescents with mild to moderate CKD. In this study of children from the largest
prospective cohort of CKD in North America, the prevalence of moderate or severe symptoms
of sleep problems or fatigue for at least one of the four CKD-related symptoms was 25%, while
the prevalence of “often” or “almost always” having trouble sleeping or low energy was 29%.
Impaired mGFR was associated with higher odds of self-reported weakness as well as parent
reports of low energy, after accounting for important demographic factors and comorbidities.
Falling asleep during the day was the most striking sleep complaint associated with kidney
function as it was two to three times more common among those with a low mGFR. On the
other hand, an association between problems with waking up too early or having issues with
alertness and mGFR was not found. However, some of the odds ratios relating mGFR to waking
up early, falling asleep during the day, and decreased alertness suggested a poorer outcome in
individuals with lower mGFR. Therefore, the lack of statistical significance may be due to the
lack of moderate or severe outcomes observed in our study population. Younger age and a
longer duration of CKD were associated with decreased daytime sleepiness and weakness/low
energy, respectively. Furthermore, trouble sleeping, low energy and weakness were strongly
associated with decrements in overall HRQOL.
In this report fatigue, as quantified by parent report of a child’s low energy and weakness, was
significantly associated with CKD severity and impaired HRQOL. Fatigue has been defined
as a subjective sense of weakness, lack of energy, and tiredness (30). Children with cancer
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define fatigue as a profound sense of being physically tired or having difficulty with body
movement (31). Furthermore, adolescents with cancer described fatigue as a changing state of
exhaustion that could include physical, mental, and emotional “tiredness” (31). Generally
fatigue questionnaires assess general tiredness (32,33), or a child’s level of energy for the
completion of activities of daily living (34). In patients with CKD, the strength of the
association between a low mGFR and fatigue was not attenuated after accounting for
demographic factors and comorbidity, suggesting that nephrologists should approach this
symptom as a manifestation of uremic exposure or other comorbidities such as anemia,
inflammation, and depression (35).
In our cohort, severe weakness had a clinically significant adverse effect on HRQOL, while
waking up early, falling asleep during the day, and decreased alertness were not associated
with HRQOL. Our findings are in concordance with two other HRQOL studies involving
children with ESRD. McKenna et al. conducted a cross-sectional assessment of HRQOL using
the PedsQL Generic Core Scale. Data were collected from 20 children with CKD, 12 on
maintenance hemodialysis (HD) or peritoneal dialysis (PD) and 27 with renal transplants and
were matched with healthy controls. Children with CKD rated their HRQOL lower than the
healthy controls (36). In another study by Goldstein et al., PedsQL data were obtained from
96 pediatric patients with ESRD receiving HD, PD or with a transplant. These participants
were then compared to healthy children (n=131 child report; n=145 parent report) to assess
their HRQOL. For all domains, HRQOL scores for the ESRD patients were significantly lower
than healthy controls (37). Timely assessment and treatment of symptoms of sleep and fatigue
may contribute to a higher level of HRQOL among children and adolescents with CKD.
A surprising finding was the inverse relationship between percentage of life with CKD and
symptomatology, with the inconsistent association between worsening mGFR and
symptomatology by parent report. We speculate that patients with a longer duration of CKD
had more time to adapt and cope with their disease. In addition, patients with genitor-urinary
causes of CKD tend to progress at a slower rate and are exposed to fewer immunosuppressive
medications (38). Similar to findings in the adult CKD population, anemia was independently
associated with weakness. This finding is particularly interesting given the median hemoglobin
of 12.6 g/dL and merits further study.
The findings of this report should be interpreted in light of several limitations. First, this report
uses items drawn from two questionnaires of the CKiD study to assess aspects of sleep and
fatigue. Use of individual items rather than scales may result in imprecise measurements of
sleep and fatigue. However, these items have face validity and are similar to items used in sleep
and fatigue scales for children and adolescents (31,39). Future work should consider extending
these findings by using a combination of validated assessment measures of sleep disorders and
fatigue (40,41) and by objective measures, such as actigraphy and polysomnography. Second,
the CKiD symptoms checklist was not validated in children with CKD. However, the items
have face validity and a 99% response rate suggesting that the respondents understood the
items. Third, the cross-sectional nature of our study precluded us from examining the
association of CKD progression with the outcomes of interest. Lastly, rather than a clinical
diagnosis, symptoms of sleep and fatigue represent the child’s or parent’s subjective perception
of symptom severity, health and well-being.
In conclusion, this report describes the extent to which sleep and fatigue symptoms are reported
by children and adolescents with mild to moderate CKD, showing a greater prevalence of sleep
problems and fatigue compared to the general population (42–45). Unlike adults, who have
completed their physiologic and intellectual maturation, children are in formative stages of
development and therefore are particularly vulnerable to the adverse effects of CKD and sleep
deprivation. Early detection and aggressive management of sleep problems and daytime fatigue
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have the potential to markedly improve functional outcomes and HRQOL in young patients
with CKD. The findings of our study should be useful for clinicians who care for children and
adolescents with CKD, as they may suggest interventions to modify preventable risk factors
for poor sleep and fatigue or interventions to lessen their impact.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Distribution of child report of trouble sleeping (panel A), parent report of trouble sleeping
(panel B), child report of low energy (panel C), and parent report of low energy (panel D)
PedsQL outcomes overall and by mGFR level.
Roumelioti et al. Page 11














Distribution of child report of weakness (panel A), waking up early (panel B), falling asleep
during the day (panel C), and decreased alertness (panel D) CKD-related symptoms overall
and by mGFR level.
Roumelioti et al. Page 12














Adjusted estimated Quality of Life scores by child report of trouble sleeping (panel A) and
parent report of trouble sleeping (panel B), and by child report of low energy (panel C) and
parent report of low energy (panel D). Values reported are mean child and parent Quality Of
Life scores and 95% confidence intervals after adjusting for age, sex, mGFR stage, income,
percentage of life with CKD, BMI percentile, low birth weight, hypertension and anemia. A
report of “often” or “almost always” having trouble sleeping was associated with lower PedsQL
scores (mean of 57.2 compared to means of 78.5 [P<0.001], 69.1 [P <0.001] and 67.8 [P=0.001]
when “never,” “almost never,” or “sometimes” were reported by the child, respectively, and a
mean of 55.9 vs. 77.3 [P<0.001], 63.2 [P=0.06] and 58.2 [P=0.6] when “never, “almost never,”
or “sometimes” were reported by the parent, respectively). A report of “often” or “almost
always” having lower energy was also associated with lower PedsQL scores (mean of 64.3 vs.
79.1 [P<0.001], 73.5 [P=0.003] and 64.0 [P<0.001] when “never,” “almost never” or
“sometimes” were reported by the child, respectively, and a mean of 52.1 vs. 82.7 [P < 0.001],
73.1 [P<0.001] and 63.3 [P<0.001] when “never,” “almost never” or “sometimes” were
reported by the parent, respectively).
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Adjusted estimated child Quality Of Life scores by parent and/or child report of symptom
severity for weakness (panel A), waking up too early (panel B), falling asleep during the day
(panel C) and decreased alertness (panel D). Values reported are mean child Quality of Life
scores and 95% confidence intervals after adjusting for age, sex, mGFR stage, income,
percentage of life with CKD, BMI percentile, hypertension and anemia. A report of “moderate”
or “severe” weakness was associated with lower quality of life (mean of 63.0 vs. 74.8 [P<0.001]
and 72.1 [P=0.01] when “no” symptoms or “mild” symptoms were reported). None of the other
symptoms were associated with the childrens’ overall PedsQL scores.
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Table 1
Characteristics of participants in the CKiD Study
No. of participants
with data available
Median (25th, 75th percentile) or
No. (%)
Age, yr 301 13.9 (10.8, 16.2)
Male Sex 301 183 (61)
White Race 301 218 (72)
Annual Income of primary
household members
285
  ≤$36,000 104 (36)
  $36,001–$75,000 89 (31)
  >$75,000 92 (32)
Measured GFR (ml/min per
    1.73m2)
301
  ≥50 99 (33)
  40-<50 65 (22)
  30-<40 70 (23)
  <30 67 (22)
Years with CKD 298 9.3 (5.0, 12.6)
Primary CKD Diagnosis 298
  GN diagnosis* 70 (23)
  non-GN (genitor-urinary,
    cystic, hereditary)
207 (69)
  non-GN (other) 21 (7)
Hypertension 301 148 (49)
  SBP ≥95th percentile for age,
    gender, height
288 34 (12)
  DBP ≥95th percentile for age,
    gender, height
289 31 (11)
Anemia 292 127 (43)
  Hemoglobin (g/dL) 292 12.6 (11.6, 13.6)
Birth Weight <2500g 285 48 (17)
Growth Markers
  Weight percentile for age and
    sex
301 44.3 (19.0, 77.6)
  Height percentile for age and
    sex
293 24.7 (8.0, 51.4)
  BMI percentile for age and sex 293 56.7 (34.3, 86.1)
Tanner Stage 286
  I 95 (33)
  II 47 (16)
  III 31 (11)
  IV 59 (21)
  V 54 (19)
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No. of participants
with data available
Median (25th, 75th percentile) or
No. (%)
Medication Usage 301
  Anti-hypertensives 221 (73)
  ESAs 53 (18)
  Growth Hormones 37 (12)
  Immunosuppressives 35 (12)
  Corticosteroids 19 (6)
  CNS-stimulating agents 15 (5)
  Antidepressants 13 (4)
N = 301.
Abbreviations: GFR, glomerular filtration rate; GN, glomerulonephritis; Conversion factors for units: GFR in mL/min/1.73m2 to mL/s/1.73m2,
×0.01667; Hemoglobin in g/dL to g/L, ×10.
*
Of the 70 participants with glomerulonephritis as cause of CKD: 23 have focal segmental glomerulosclerosis, 12 have hemolytic uremic syndrome,
5 have familial nephritis (Alport’s), 5 have IgA nephropathy (Berger’s), 5 have systemic immunological disease, 3 have chronic glomerulonephritis,
3 have membranoproliferative glomerulonephritis type I, 2 have idiopathic crescentic glomerulonephritis, 2 have congenital nephritic syndrome, 1
has membranous nephropathy, 1 has henoch schoenlein purpura, 1 has membranoproliferative glomerulonephritis type II, 7 have other glomerular
causes of CKD.
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Table 2
Multivariate Relationships between Pediatric Quality of Life Inventory outcomes and cohort characteristics.












%; OR (95% CI)
No. No.=237 No.=214 No.=234 No.=222
Measured GFRa
  ≥50 33%; 1 (ref) 29%; 1 (ref) 33%; 1 (ref) 31%; 1 (ref)






24%; 2.07 (1.05, 4.09)*






27%; 2.35 (1.17, 4.72)*






18%; 2.59 (1.15, 5.85)*
Family Income
  ≤ $36,000 NA 37%; 1 (ref) NA 37%; 1 (ref)
  $36,000–≤$75,000 NA 30%; 0.82
(0.44, 1.52)
NA 31%; 0.82 (0.44, 1.50)
  >$75,000 NA 33%; 0.54
(0.30, 0.99) *
NA 32%; 0.32 (0.16, 0.67)*
% of life with CKD
  <25% NA NA 17%; 1 (ref) 16%; 1 (ref)
  25% to <75% NA NA 30%; 0.35
(0.17, 0.71)*
29%; 0.47 (0.22, 1.02)
  75% to 100% NA NA 53%; 0.34
(0.17, 0.65)*
55%; 0.32 (0.16, 0.67)*
Growth Markers
  Birth Weight <2500g** NA 18%; 1.55
(0.81, 2.95)
NA NA
  BMI percentileb
    <35 26%; 1 (ref) NA NA NA
    35 to <60 23%; 1.16
(0.59, 2.30)
NA NA NA
    60 to <85 24%; 0.90
(0.45, 1.79)
NA NA NA




  Hypertensiveb 48%; 0.59
(0.36, 0.97)*
NA NA NA





Global P-value for model
significance P=0.07 P=0.4 P=0.005 P<0.001
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*
indicates significance at the 0.05 level; OR, odds ratio; CI, confidence interval; CKD, chronic kidney disease; NA, not applicable; ref, reference.
**
reference value is ≥2500 g[ND3]
a
Glomerular filtration Rate measured in ml/min/1.73m2.
b
Age and sex specific percentiles using standard growth charts for United States children.
b
Systolic or Diastolic Blood Pressure >95th percentile for age, sex, height or self-report of hypertension with concurrent report of anti-hypertensive
medication.
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Table 3
Multivariate Relationships between Chronic Kidney Disease-related symptoms and cohort characteristics
Weakness












No. No.=224 No.=264 No.=246 No.=268
Measured GFR a
  ≥50 29%; 1 (ref) 33%; 1 (ref) 31%; 1 (ref) 31%; 1 (ref)

























  Age (years)
    8 to ≤11 NA NA 30%; 1 (ref) 28%; 1 (ref)












  non-White Race NA NA NA 26%; 1.71
(0.72, 4.05)
  Family Income
    ≤ $36,000 36%; 1 (ref) 37%; 1 (ref) 37%; 1 (ref) NA














% of life with CKD
  <25% 17%; 1 (ref) NA NA 17%; 1 (ref)
  25% to <75% 26%; 0.18 (0.07,
0.51)*
NA NA 29%; 0.73
(0.26, 2.04)
  75% to 100% 56%; 0.29 (0.13,
0.68)*
NA NA 54%; 0.55
(0.20, 1.48)
Growth Markers
  Birth Weight <2500g** 19%; 2.74 (1.23,
6.06)*
NA NA NA
  BMI percentile b
    <35 25%; 1 (ref) NA NA NA
    35 to <60 26%; 0.79 (0.33,
1.87)
NA NA NA













Roumelioti et al. Page 20
Weakness












    60 to <85 23%; 0.84 (0.33,
2.12)
NA NA NA
    ≥85 26%; 0.57 (0.21,
1.50)
NA NA NA
  Tanner Stage IV or V 37%; 0.54 (0.27,
1.10)
NA 37%; 0.56 (0.24,
1.31)
NA
Anemia 44%; 2.20 (1.05,
4.63)*




Global P-value for model
significance P<0.001 P=0.02 P=0.001 P=0.3
OR, odds ratio; CI, confidence interval; CKD, chronic kidney Disease; NA, not applicable.
a
Glomerular filtration Rate measured in ml/min/1.73m2.
b
Age and sex specific percentiles using standard growth charts for United States children
*
indicates significance at the 0.05 level
**
reference value is ≥2500 g
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